go777 slot login

go777 slot login COPENHAGEN, Denmark--(BUSINESS WIRE)--Dec 8, 2024-- Genmab A/S (Nasdaq: GMAB): Genmab A/S (Nasdaq: GMAB) today announced results from the Phase 1b/2 EPCORE ® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in difficult-to-treat adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab monotherapy. These results, from the monotherapy expansion (EXP) cohort (n=23) of the trial, along with the first safety data from the optimization (OPT) cohort, were presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), during the ASH Annual Meeting Press Program. The data will be presented during an oral session on December 9, 2024. In the EXP cohort, the median time to response was two (2.0) months and the median time to CR was 5.6 months. Among all patients in the cohort, median progression-free survival (PFS) was 12.8 months and median overall survival (OS) was not reached (median follow-up was 22.8 months). An estimated 65 percent of patients were alive at 15 months. Among 12 responders evaluable for minimal residual disease (MRD) by next-generation sequencing in peripheral blood, nine patients (75 percent) had undetectable MRD. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) in the EXP cohort were cytokine release syndrome (CRS; 96 percent), diarrhea (48 percent), peripheral edema (48 percent), fatigue (43 percent), and injection-site reaction (43 percent). Cytopenias were common (anemia, 65 percent; thrombocytopenia, 65 percent; neutropenia, 48 percent); however, most patients had baseline anemia and thrombocytopenia, suggesting that these events were largely disease-related. Three cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported (one Grade 1; two Grade 2), and there was one clinical tumor lysis syndrome (CTLS) case (Grade 2). These cases did not lead to treatment discontinuation. Four fatal TEAEs occurred - two cases of pneumonia, one case of sepsis and one case of squamous cell carcinoma of the skin. The EXP cohort followed a 2-step step-up dose regimen, and CRS was manageable and primarily low grade (9 percent Grade 1, 70 percent Grade 2, 17 percent Grade 3). In the first data from the separate OPT cohort, which followed a 3-step step-up dose regimen, CRS severity was substantially reduced with only low-grade events (71 percent Grade 1, 12 percent Grade 2). In both cohorts, CRS events primarily occurred following the first full dose, and none led to treatment discontinuation. No ICANS or CTLS cases were reported in the OPT cohort. “These EPCORE CLL-1 data are encouraging, especially as the majority of patients were heavily pre-treated with at least four lines of therapy,” said Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus, Professor and Director of Early Clinical Therapeutics and Associate Director of the Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. “Despite progress in treating chronic lymphocytic leukemia, there remains a tremendous need for additional therapeutic options for high-risk patients whose disease has progressed following standard chemoimmunotherapy and targeted therapies.” Additional data from the EXP cohort showed high response rates in patients with high-risk factors treated with epcoritamab, including TP53 aberrations, IGHV-unmutated disease and double-exposed disease – prognostic markers that are associated with disease progression and decreased survival. i,ii,iii In patients with TP53 aberrations (n=15), the ORR was 67 percent with a CR of 33 percent. Among patients with IGHV-unmutated disease (n=16), the ORR was 63 percent, and the CR was 44 percent. In double-refractory patients, the ORR was 53 percent, and the CR was 37 percent. All patients in the trial had prior chemoimmunotherapy, and most patients had previously received targeted therapies such as BTK and BCL2 inhibitors (double-exposed) and had high-risk disease characteristics. “Chronic lymphocytic leukemia is incurable, and patients often need a variety of treatments throughout their lifetime, especially if their disease has high-risk prognostic factors, has relapsed or has become refractory to the current standard-of-care, including targeted therapies,” said Dr. Judith Klimovsky, Executive Vice President & Chief Development Officer, Genmab. “These early data show the potential therapeutic applicability of epcoritamab in relapsed or refractory chronic lymphocytic leukemia, and further reinforce the potential of epcoritamab as a core therapy for the treatment of B-cell malignancies.” Use of epcoritamab in CLL is not approved in the U.S. or in the EU or in any other territory. The safety and efficacy of epcoritamab for use in CLL have not been established. About Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affecting over 200,000 people in the United States alone. iv Chronic lymphocytic leukemia can be classified as either slow growing (indolent) or fast growing (aggressive). v CLL is incurable, and many patients will likely relapse and progress on frontline therapies. vi Most patients will experience consecutive episodes of disease progression and will require several lines of treatment in their lifetime. vii,viii About the EPCORE ® CLL-1 Trial EPCORE ® CLL-1 is a Phase 1b/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of epcoritamab as a monotherapy and in combination with standard of care agents in patients with difficult-to-treat relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), R/R small lymphocytic lymphoma (SLL) and Richter's Syndrome (RS). The trial consists of two parts: a dose-escalation phase (Phase 1b) and an expansion phase (Phase 2). Patients with RS are only included in the expansion phase. The primary objective of Phase 1b is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of epcoritamab monotherapy and epcoritamab plus venetoclax in participants with R/R CLL. The purpose of Phase 2 is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab plus venetoclax for patients with R/R CLL and SLL. Additionally, epcoritamab monotherapy and combination therapy will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 04623541). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. ix Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigator's choice chemotherapy ( NCT04628494 ), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL ( NCT05578976 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with R/R FL ( NCT05409066 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) compared to chemoimmunotherapy in patients with previously untreated FL ( NCT06191744 ), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL ( NCT06508658 ). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information. EPKINLY ® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. Important Warnings—EPKINLY can cause serious side effects, including: People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Full Prescribing Information and Medication Guide , including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSOTM. EPCORE ®, EPKINLY ®, TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Campo, et al. TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics. Haematologica . 2018 Nov 15;103(12):1956–1968. https://haematologica.org/article/view/8691 . ii Galieni, et al. Unmutated IGHV at Diagnosis in Patients With Early Stage CLL Independently Predicts for Shorter Follow-Up Time to First Treatment (TTFT). Leukemia Research. 2024. https://doi.org/10.1016/j.leukres.2024.107541 . iii Zuber, et al. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review. Cancer Medicine . 2024. https://doi.org/10.1002/cam4.70258 . iv Fedele, et al. Chronic Lymphocytic Leukemia: Time to Care for the Survivors. Journal of Clinical Oncology . 2024. https://ascopubs.org/doi/10.1200/JCO.23.02738 . v Penn Medicine. Chronic Lymphocytic Leukemia (CLL). Accessed November 2024. https://www.pennmedicine.org/cancer/types-of-cancer/leukemia/types-of-leukemia/chronic-lymphocytic-leukemia . vi Odetola, et al. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Curr Hematol Malig Rep . 2023 Jun 6:1–14. doi: 10.1007/s11899-023-00700-z vii Moreno, Carol. Standard Treatment Approaches for Relapsed/Refractory Chronic Lymphocytic Leukemia After Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program . 2020 Dec 4;2020(1):33-40. doi: 10.1182/hematology.2020000086. viii Leukemia & Lymphoma Society. Relapsed and Refractory CLL. Accessed November 2024. https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/relapsed-and-refractory . ix Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine . 2020;52:102625. doi: 10.1016/j.ebiom.2019.102625. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208951291/en/ CONTACT: David Freundel, Senior Director, Global R&D & Portfolio Communications T: +1 609 430 2481; E:dafr@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E:acn@genmab.com KEYWORD: DENMARK EUROPE INDUSTRY KEYWORD: RESEARCH FDA CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE ONCOLOGY SOURCE: Genmab A/S Copyright Business Wire 2024. PUB: 12/08/2024 11:00 AM/DISC: 12/08/2024 11:02 AM http://www.businesswire.com/news/home/20241208951291/enNew Orleans Pelicans star center Zion Williamson has started the conditioning phase of his rehab from a left hamstring strain and is expected to return to practice next week, the team announced Tuesday. Williamson, who is considered week-to-week, has been sidelined since Nov. 6. The two-time All-Star has played in just six games this season, averaging 22.7 points, 8.0 rebounds and 5.3 assists. New Orleans selected Williamson with the top overall pick in the 2019 NBA Draft. His time with the Pelicans has been marked by multiple injuries, starting with a torn meniscus during the preseason of his rookie year. Williamson has played in just 190 career games over five seasons, while also missing the entire 2021-22 campaign. He has averaged 24.6 points, 6.6 rebounds and 4.2 assists. This article first appeared on Field Level Media and was syndicated with permission.

None

HARRISBURG, Pa. (AP) — Former Philadelphia Eagles running back Wendell Smallwood Jr. has pleaded guilty to federal fraud charges after he was accused of submitting fraudulent tax returns and applications for hundreds of thousands of dollars in COVID-19 pandemic aid programs. The signed plea agreement was approved Friday by a federal judge in Delaware. Smallwood, of Mullica Hill, New Jersey, faces sentencing in May on the three fraud charges. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a weekNone

Caprock Group LLC Has $369,000 Stock Position in MasTec, Inc. (NYSE:MTZ)

Chelsea defender Marc Cucurella changed his cleats just 12 minutes into the game after his slips contributed to both of Tottenham's early goals in the teams' London derby in the Premier League on Sunday. The Spain international ceded possession by slipping on the turf at Tottenham Hotspur Stadium in the fifth and 11th minutes — and from the ensuing attacks, Spurs scored through Dominic Solanke and Dejan Kulusevski. Immediately after Kulusevski's shot hit the net to make it 2-0, Cucurella sprinted to the sideline while shrugging his shoulders and pointed to his cleats. He took them off and threw them away in disgust before putting on new ones. It seemed to work. Within six minutes, he provided the pass that led to Jadon Sancho scoring for Chelsea to make it 2-1. Chelsea went on to win 4-3 — and Cucurella posted a photo on social media after the match, showing the first cleats he wore nestled in a bin. “It almost slipped away,” Cucurella wrote on Instagram Stories, “but proud of the amazing team effort to turn things around.” AP soccer: https://apnews.com/hub/soccerWhenever President Zelenskyy attends international events he is inevitably the centre of gravity, and last week’s EU summit in Brussels was no exception. This summit was particularly significant for Ukraine. For Zelenskyy, an event that brought all the European leaders together was not to be missed, especially since he has recently been actively negotiating with Ukraine’s partners to establish safeguards that would mitigate the risks inherent in US President-elect Donald Trump’s return to power. Zelenskyy argues that any truce or "freeze" in the Russo-Ukrainian war would be extremely dangerous unless accompanied by effective security guarantees. These guarantees could take various forms. One of the options discussed in Brussels was the deployment of a peacekeeping mission in Ukraine following any future ceasefire. Some believe that the presence of Western peacekeepers would act as a deterrent for Vladimir Putin, preventing him from launching a new full-scale war. Even if this is done, Zelenskyy is insistent that Ukraine’s NATO membership must remain on the table. Meanwhile, there has been a significant shift in Ukraine’s public stance lately. Ukraine has adopted robust rhetoric and a strong position without concessions. The change applies to both NATO-related matters and gas transit issues, regarding which Zelenskyy came under pressure in Brussels but stood firm. (adsbygoogle=window.adsbygoogle||[]).push({}) President Zelenskyy's visit to Brussels was linked to the EU summit, which brings the leaders of all the member states together. But the opportunity to speak with everyone at once also brings limitations. How can there be a serious discussion about a joint strategy on relations with Trump when one of the participants is Viktor Orbán, Hungary’s pro-Putin and pro-Trump prime minister? That meant that in addition to taking part in the summit, Ukraine needed to hold a meeting in a smaller circle. But as soon as Kyiv began to make arrangements, EU officials objected, arguing that if the talks were being conducted under the EU umbrella, it would be inappropriate to invite only Ukraine’s "key partners" and exclude others. The idea of meeting at NATO headquarters was beset with similar challenges. Hungary is a member of the Alliance, and the position of Türkiye, for example, also raises serious concerns. So a unique format was created: the leaders gathered at the residence of NATO Secretary General Mark Rutte. In reality, however, neither Rutte nor NATO had organised the meeting – it was arranged by Ukraine. The list of attendees is worthy of note. In addition to Ukraine, the NATO Secretary General and the EU leadership, the meeting was attended by representatives from seven European countries: France , Germany and Italy (the EU’s three largest economies), the United Kingdom (a key donor to Ukraine's Armed Forces), Denmark and the Netherlands (key supporters of Ukraine’s military who have facilitated the supply of F-16s), and Poland, which recently stopped providing military aid but remains critical for weapons supply logistics. It's also important to note who wasn't there. Why was the group of Ukraine’s key partners kept so small? Spain, the EU's fourth-largest economy, has lagged behind other countries in terms of its financial contributions and the boldness of its decisions. The Baltic states, although vocal in their support for Ukraine, might have been seen as overly radical, which could have alienated others. Ukraine’s neighbour Romania wasn’t invited either, which did not go down well in Bucharest. President Klaus Iohannis even had to explain the situation to journalists. Romania is currently in a transitional political phase as it awaits election results, and its military aid remains limited. (adsbygoogle=window.adsbygoogle||[]).push({}) Several European Pravda sources confirmed that during this and other meetings, the leaders discussed security guarantees for Ukraine. Pressure on Kyiv to agree to a ceasefire is expected to increase in 2025. Trump isn’t the only leader who has openly advocated for this. Zelenskyy has argued that without robust guarantees, Putin would use any truce to build his forces back up and launch another attack. So conditions must be put in place to at least hinder Russia’s economic recovery (e.g. by maintaining sanctions). There are indications that this message was heard. How can a new Russian offensive be made impossible? One of the options discussed in Brussels is to deploy a peacekeeping mission along the line of the Russian occupation, involving NATO troops. President Zelenskyy attributes this idea to French President Emmanuel Macron. "We support Macron's initiative. NATO membership clearly remains the best security guarantee for us. But until Ukraine joins NATO, this could be considered." The talks at Rutte’s residence were not aimed at reaching any agreement. This idea is still in its infancy. Zelenskyy emphasised that the mere presence of peacekeepers alone would not suffice as a security guarantee. The devil is in the details. One of the key questions is what would happen if Russia started gearing up for another attack or shelling resumed across the contact line. Would the peacekeepers be withdrawn due to security risks? Kyiv vividly remembers the events of early 2022, when most Western embassies left Kyiv or even Ukraine altogether. Could the same happen with peacekeepers? If so, the mission would hold little value. Another crucial point, European Pravda’s sources emphasised, is that the peacekeeping mission must include the United States. This would give the guarantees more weight in Moscow's eyes. "Also, we realise that without US involvement, the EU countries alone would not be able to provide enough peacekeepers for the mission to be effective," one source explained. (adsbygoogle=window.adsbygoogle||[]).push({}) President Zelenskyy repeatedly emphasised in Brussels that NATO membership remains the only truly effective security guarantee for Ukraine and the other options are merely interim measures. But the West is not ready to take that step, and Donald Trump’s team is extremely dubious about inviting Ukraine to join NATO. At one point there were hopes of appealing to Trump’s ambition by framing it as: "Biden was too weak to bring Ukraine into NATO, but you’re a bold leader who can." But it was clear from the very first contact with Trump’s team that there is no point raising this issue right now. Kyiv’s initial response was to come up with creative crisis solutions, leading to Zelenskyy’s recent talk of partial NATO membership with guarantees only for certain parts of Ukrainian territory. The hope was that this proposal might sway the new US administration. However, since mentioning the idea several times in late November, Zelenskyy has not revisited it. According to European Pravda sources, Ukraine received a clear message from its Western allies that can be summed up in a single word: "Stop!" They explained to Kyiv that this idea is perceived as a concession. It won’t help in negotiations with Trump and could even backfire. The allies’ message was: "This already looks like Ukraine has compromised. Let’s focus on other discussions." The President’s Office got the message and has adjusted its "preparing for Trump" strategy. The current strategy is now based on firmness. Firmness, though, is only possible if Ukraine is not acting alone. Ukraine needs to agree joint actions and strategies with its European partners – something Zelenskyy has recently been focusing on. Ukraine has also begun to "show its character" more openly. That doesn’t just apply to NATO, where Kyiv refuses to accept rejection and continues to insist on membership. The increasingly robust rhetoric concerning Putin – Zelenskyy recently called him a "dumbass" – is part of the same strategy. This and other strong statements are intended to send a clear signal that there is no point negotiating with Putin. Ukraine’s tough stance has also become evident in its attitude to Viktor Orbán and his initiatives, which has been notably assertive in recent weeks. Another key issue on which Zelenskyy stood firm in Brussels was his absolute refusal to transit Russian gas, even if it is disguised as Azerbaijani . When Slovak Prime Minister Robert Fico attempted to persuade Zelenskyy otherwise during the Brussels meeting, he was firmly rebuffed. Zelenskyy explained that there is only one condition under which he would agree to transit Russian gas: "If a European country is willing to take the gas and not pay the money to Russia until the war is over, then we could think about it. But we will not admit the possibility of additional billions being earned from our blood, from the lives of our citizens," he stated. Sergiy Sydorenko, Editor, European Pravda, from Brussels

Rarely does a college basketball game provide such stark contrast between the sport's haves and have-nots as when Jackson State faces No. 9 Kentucky on Friday in Lexington, Ky. While Kentucky claims eight NCAA Tournament crowns and the most wins in college basketball history, Jackson State has never won an NCAA Tournament game and enters the matchup looking for its first win of the season. Impressive tradition and current record aside, Kentucky (4-0) returned no scholarship players from last season's team that was knocked off by Oakland in the NCAA Tournament. New coach Mark Pope and his essentially all-new Wildcats are off to a promising start. Through four games, Kentucky is averaging 94.3 points per game, and with 11.5 3-pointers made per game, the team is on pace to set a school record from long distance. The Wildcats boast six double-figure scorers with transfer guards Otega Oweh (from Oklahoma, 15.0 ppg) and Koby Brea (from Dayton, 14.5 ppg) leading the team. The Wildcats defeated Duke 77-72 on Nov. 12 but showed few signs of an emotional letdown in Tuesday's 97-68 win over a Lipscomb team picked to win the Atlantic Sun Conference in the preseason. Kentucky drained a dozen 3-pointers while outrebounding their visitors 43-28. Guard Jaxson Robinson, held to a single point by Duke, dropped 20 points to lead the Kentucky attack. Afterward, Pope praised his team's focus, saying, "The last game was over and it was kind of on to, ‘How do we get better?' That's the only thing we talk about." Lipscomb coach Lennie Acuff also delivered a ringing endorsement, calling Kentucky "the best offensive Power Four team we've played in my six years at Lipscomb." Jackson State (0-5) and third-year coach Mo Williams are looking for something positive to build upon. Not only are the Tigers winless, but they have lost each game by nine or more points. Sophomore guard Jayme Mitchell Jr. (13.8 ppg) is the leading scorer, but the team shoots just 35.8 percent while allowing opponents to shoot 52.3 percent. The Tigers played on Wednesday at Western Kentucky, where they lost 79-62. Reserve Tamarion Hoover had a breakout game with 18 points to lead Jackson State, but the host Hilltoppers canned 14 3-point shots and outrebounded the Tigers 42-35 to grab the win. Earlier, Williams, who played against Kentucky while a student at Alabama, admitted the difficulties of a challenging nonconference schedule for his team. "Our goal is not to win 13 nonconference games," Williams said. "We're already at a disadvantage in that regard. We use these games to get us ready for conference play and for March Madness." Jackson State has not made the NCAA Tournament since 2007. The Tigers had a perfect regular-season record (11-0) in the Southwestern Athletic Conference in 2020-21 but lost in the league tournament. Kentucky has never played Jackson State before, but the game is being billed as part of a Unity Series of matchups in which Kentucky hosts members of the SWAC to raise awareness of Historical Black Colleges and Universities and provide funds for those schools. Past Unity Series opponents have been Southern in December 2021 and Florida A&M in December 2022. --Field Level Media

Allo has secured a $100 million bitcoin-backed credit facility to expand its platform that helps institutions and individuals participate in crypto lending. The company’s solution bridges traditional finance with blockchain technology, Allo said in a Tuesday (Dec. 23) press release . “Bolstering its position in the bitcoin ecosystem, Allo has staked over 544 BTC (valued at $50M+) through the Babylon Bitcoin Staking Protocol ,” the company said in the release. “This positions Allo as a key player in enabling bitcoin-secured networks, with its BTC staking solution minting the $alloBTC token featured prominently on DeFiLlama .” Allo also highlighted in the release other recent developments, including its inclusion in the Binance Labs and BNB Chain MVB Accelerator program, its preparations to launch its native $RWA cryptocurrency, and its efforts in tokenizing real-world assets. The company’s financing round was facilitated by a consortium of lenders that includes Greengage , per the release. “We’re excited to support this much-needed new venture and look forward to seeing great things to come,” Greengage CEO Sean Kiernan said in the release. PYMNTS reported in October 2023 that crypto lending was making a comeback, with several exchanges debuting new offerings. Cryptocurrency exchange Coinbase rolled out a digital asset lending program for its institutional Prime clients in September 2023, saying it allows for lending “under standardized terms in a product that qualifies for a Regulation D exemption.” “Coinbase is working to update the financial system that was built over 100 years ago, leveraging crypto to provide people with more economic freedom and opportunity,” a company spokesperson told PYMNTS at the time. “To advance this purpose, Coinbase is building the most trusted crypto products and services, and supporting other builders to bring 1 billion people into crypto.” In July 2023, crypto lender Aave debuted its first stablecoin, GHO , saying the coin was live on the ethereum network. “GHO was developed with the same goal as the Aave Protocol: to enable a people-powered financial ecosystem, accessible to all, that everyone can benefit from,” the company said at the time. “With the Aave Protocol and GHO, people around the world have equal access to the same financial tools that are based on transparent and decentralized technology.”

Bill Clinton discharged from hospital after being treated for fluRechargeable Screwdriver Switches Market Outlook and Future Projections for 2030 11-24-2024 02:07 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: Dhirtek Business Research and Consulting Rechargeable Screwdriver Switches Market The rechargeable screwdriver switches market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the current state of the rechargeable screwdriver switches market but also forecasts its future trends. Scope and Purpose This report serves as an extensive resource, thoughtfully curated to deliver actionable intelligence to industry stakeholders. It covers critical elements such as market dynamics, competitive environments, growth opportunities, challenges, and regional differences. The insights provided go beyond mere descriptions, offering a valuable tool for stakeholders to refine their strategies and make informed choices in a competitive market. Request for Sample Report: https://www.dhirtekbusinessresearch.com/market-report/Rechargeable-Screwdriver-Switches-Market/request-for-sample-report Comprehensive Market Analysis We are committed to providing a thorough analysis that explores every aspect of market growth, including shifts in consumer preferences and technological innovations driving demand for rechargeable screwdriver switches products. We also address the challenges faced by the industry, such as economic uncertainties and intense competition, offering insights to help stakeholders navigate these complexities. Key Players in the Rechargeable Screwdriver Switches Market: Defond Marquardt GmbH Weida Machinery HUAJIE Kedu Electric CPX Switch Chuanmu Electric Tyco Electronics Yueqing Jlevel Electrical Guosheng Instrument TACLEX Baokezhen Shunfa Bremas Superior Electric Strategic Guidance for the Future This report invites stakeholders to delve into a detailed examination of the competitive landscape. By profiling key players in the rechargeable screwdriver switches market and analyzing their strategies, we offer crucial insights to help industry participants make informed strategic decisions. Whether it's about outpacing competitors or learning from successful approaches, our analysis is designed to guide stakeholders toward success. Anticipated Insights Understanding the diverse segments within the rechargeable screwdriver switches market is critical to success. Our report breaks down segment sizes, potential growth trajectories, and key trends, offering actionable insights that allow stakeholders to develop targeted strategies and optimize resource allocation. The knowledge provided empowers stakeholders to navigate the complexities of the rechargeable screwdriver switches market with clarity and confidence. Balancing Market Forces and Strategic Impact This report delivers a comprehensive analysis of the factors shaping the rechargeable screwdriver switches market. By evaluating both the drivers of market growth and the obstacles that could impede it, stakeholders gain a holistic understanding of the market's dynamics. For manufacturers, this analysis helps align innovation efforts with consumer demands and regulatory trends, while investors and decision-makers gain a deeper understanding of economic risks and supply chain vulnerabilities, allowing them to make more informed strategic choices. Our goal is to provide stakeholders with the knowledge needed to confidently and successfully navigate the rechargeable screwdriver switches market. Competitive Landscape Our in-depth examination of the rechargeable screwdriver switches market's competitive landscape highlights key players, scrutinizing their strategies and impacts on the industry. By analyzing the approaches of major companies, stakeholders gain a valuable understanding of market dynamics and can leverage these insights to identify growth opportunities, innovate, and make informed strategic decisions. Market Segmentation The report begins with a detailed analysis of the unique characteristics defining each segment within the rechargeable screwdriver switches market. Segmentation can occur across various dimensions, including product types, customer demographics, or specific use cases. Understanding these differences allows stakeholders to tailor their strategies, products, and marketing efforts to meet the specific needs of each segment, enhancing competitive positioning and maximizing opportunities for success. Market Segments: Product Type: DC and AC Speed Control Switch Single Speed Switch Micro Switch Trigger Switch Rocker Switch Others Application: Cordless Corded Market Size and Segment Growth Potential A crucial part of the report focuses on understanding the size and significance of each market segment. We provide quantitative data that illustrates the market share and contribution of each segment, enabling stakeholders to make informed decisions regarding resource allocation, strategic prioritization, and investment. This section offers insights into the growth potential of each segment, including factors driving future expansion, evolving consumer preferences, and technological adoption. Conclusion This report serves as a strategic guide for stakeholders in the rechargeable screwdriver switches market, offering comprehensive insights into market segmentation, competitive dynamics, and growth potential. By understanding the market's complexities and emerging opportunities, industry participants can make well-informed decisions that drive success and innovation in this rapidly evolving market. Other Reports Ferronickel Smelting Equipment Market https://www.dhirtekbusinessresearch.com/market-report/Ferronickel-Smelting-Equipment-Market Industrial Storage Tank Market https://www.dhirtekbusinessresearch.com/market-report/Industrial-Storage-Tank-Market Sterilization Chemical Indicator Tape Market https://www.dhirtekbusinessresearch.com/market-report/Sterilization-Chemical-Indicator-Tape-Market Freon-free Chiller Market https://www.dhirtekbusinessresearch.com/market-report/Freon-free-Chiller-Market "Contact Us Dhirtek Business Research and Consulting Private Limited Contact No: +91 7580990088 Email Id: sales@dhirtekbusinessresearch.com" "About Us Dhirtek Business Research & Consulting Pvt Ltd is a global market research and consulting services provider headquartered in India. We offer our customers syndicated research reports, customized research reports, and consulting services. Our objective is to enable our clientele to achieve transformational progress and help them to make better strategic business decisions and enhance their global presence. We serve numerous companies worldwide, mobilizing our seasoned workforce to help companies shape their development through proper channeling and execution. We offer our services to large enterprises, start-ups, non-profit organizations, universities, and government agencies. The renowned institutions of various countries and Fortune 500 businesses use our market research services to understand the business environment at the global, regional, and country levels. Our market research reports offer thousands of statistical information and analysis of various industries at a granular level." This release was published on openPR.

Progress is being made to reclaim the Dixie plant building in Wilson, to reuse the Lehigh Valley Dairy site on MacArthur Road in Whitehall, the PPL Tower in downtown Allentown, Martin Tower land in west Bethlehem, and former Mack Truck buildings on Allentown’s southside. This is happening while Moravian Bethlehem has been designated a UNESCO World Heritage site for its preservation of the past.Penneys block heel boot €85 cheaper than designer rival has customers flocking